However, inhibiting the normal function of AChE as a competitive substrate for acetylcholine or as a released parent drug and as an AChE inhibitor can have additional positive effects, particularly in the AD patient’s brain, i.e., an individual suffering from intensified AChE activity [62]. This evidence concerns the gene ACHE and Alzheimer disease.